EVE is an mTOR inhibitor that has emerged as an effective drug in the management of malignancies, such as breast cancer, renal cell carcinoma, subependymal giant cell astrocytoma, and neuroendocrine tumors. Here, MTOR is linked to neuroendocrine neoplasm.